Tags

Type your tag names separated by a space and hit enter

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates.
bioRxiv. 2020 May 28B

Abstract

The ongoing COVID-19 pandemic, caused by infection with SARS-CoV-2, is having a dramatic and deleterious impact on health services and the global economy. Grim public health statistics highlight the need for vaccines that can rapidly confer protection after a single dose and be manufactured using components suitable for scale-up and efficient distribution. In response, we have rapidly developed repRNA-CoV2S, a stable and highly immunogenic vaccine candidate comprised of an RNA replicon formulated with a novel Lipid InOrganic Nanoparticle (LION) designed to enhance vaccine stability, delivery and immunogenicity. We show that intramuscular injection of LION/repRNA-CoV2S elicits robust anti-SARS-CoV-2 spike protein IgG antibody isotypes indicative of a Type 1 T helper response as well as potent T cell responses in mice. Importantly, a single-dose administration in nonhuman primates elicited antibody responses that potently neutralized SARS-CoV-2. These data support further development of LION/repRNA-CoV2S as a vaccine candidate for prophylactic protection from SARS-CoV-2 infection.

Authors+Show Affiliations

Department of Microbiology, University of Washington, Seattle, WA. Host Directed Therapeutics (HDT) Bio Corp, Seattle, WA.Host Directed Therapeutics (HDT) Bio Corp, Seattle, WA. PAI Life Sciences, Seattle, WA.Department of Biochemistry, University of Washington, Seattle, WA.Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA. Department of Immunology, University of Washington, Seattle, WA.Department of Microbiology, University of Washington, Seattle, WA. Washington National Primate Research Center, Seattle, WA.Department of Microbiology, University of Washington, Seattle, WA.Department of Microbiology, University of Washington, Seattle, WA. PAI Life Sciences, Seattle, WA.Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT.Department of Microbiology, University of Washington, Seattle, WA.Department of Microbiology, University of Washington, Seattle, WA. Washington National Primate Research Center, Seattle, WA.Department of Microbiology, University of Washington, Seattle, WA.PAI Life Sciences, Seattle, WA.Washington National Primate Research Center, Seattle, WA.Host Directed Therapeutics (HDT) Bio Corp, Seattle, WA.Host Directed Therapeutics (HDT) Bio Corp, Seattle, WA. PAI Life Sciences, Seattle, WA. Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA.PAI Life Sciences, Seattle, WA. Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA.Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT.Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT.Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA. Washington National Primate Research Center, Seattle, WA. Department of Immunology, University of Washington, Seattle, WA.Department of Biochemistry, University of Washington, Seattle, WA.Host Directed Therapeutics (HDT) Bio Corp, Seattle, WA.Department of Microbiology, University of Washington, Seattle, WA. Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA. Washington National Primate Research Center, Seattle, WA.

Pub Type(s)

Preprint

Language

eng

PubMed ID

32511417

Citation

Erasmus, Jesse H., et al. "Single-dose Replicating RNA Vaccine Induces Neutralizing Antibodies Against SARS-CoV-2 in Nonhuman Primates." BioRxiv : the Preprint Server for Biology, 2020.
Erasmus JH, Khandhar AP, Walls AC, et al. Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates. bioRxiv. 2020.
Erasmus, J. H., Khandhar, A. P., Walls, A. C., Hemann, E. A., O'Connor, M. A., Murapa, P., Archer, J., Leventhal, S., Fuller, J., Lewis, T., Draves, K. E., Randall, S., Guerriero, K. A., Duthie, M. S., Carter, D., Reed, S. G., Hawman, D. W., Feldmann, H., Gale, M., ... Fuller, D. H. (2020). Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates. BioRxiv : the Preprint Server for Biology. https://doi.org/10.1101/2020.05.28.121640
Erasmus JH, et al. Single-dose Replicating RNA Vaccine Induces Neutralizing Antibodies Against SARS-CoV-2 in Nonhuman Primates. bioRxiv. 2020 May 28; PubMed PMID: 32511417.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates. AU - Erasmus,Jesse H, AU - Khandhar,Amit P, AU - Walls,Alexandra C, AU - Hemann,Emily A, AU - O'Connor,Megan A, AU - Murapa,Patience, AU - Archer,Jacob, AU - Leventhal,Shanna, AU - Fuller,Jim, AU - Lewis,Thomas, AU - Draves,Kevin E, AU - Randall,Samantha, AU - Guerriero,Kathryn A, AU - Duthie,Malcolm S, AU - Carter,Darrick, AU - Reed,Steven G, AU - Hawman,David W, AU - Feldmann,Heinz, AU - Gale,Michael,Jr AU - Veesler,David, AU - Berglund,Peter, AU - Fuller,Deborah Heydenburg, Y1 - 2020/05/28/ PY - 2020/6/9/entrez PY - 2020/6/9/pubmed PY - 2020/6/9/medline KW - RNA KW - SARS-CoV-2 KW - coronavirus KW - nanoparticle KW - nonhuman primates KW - replicon KW - vaccine JF - bioRxiv : the preprint server for biology JO - bioRxiv N2 - The ongoing COVID-19 pandemic, caused by infection with SARS-CoV-2, is having a dramatic and deleterious impact on health services and the global economy. Grim public health statistics highlight the need for vaccines that can rapidly confer protection after a single dose and be manufactured using components suitable for scale-up and efficient distribution. In response, we have rapidly developed repRNA-CoV2S, a stable and highly immunogenic vaccine candidate comprised of an RNA replicon formulated with a novel Lipid InOrganic Nanoparticle (LION) designed to enhance vaccine stability, delivery and immunogenicity. We show that intramuscular injection of LION/repRNA-CoV2S elicits robust anti-SARS-CoV-2 spike protein IgG antibody isotypes indicative of a Type 1 T helper response as well as potent T cell responses in mice. Importantly, a single-dose administration in nonhuman primates elicited antibody responses that potently neutralized SARS-CoV-2. These data support further development of LION/repRNA-CoV2S as a vaccine candidate for prophylactic protection from SARS-CoV-2 infection. UR - https://www.unboundmedicine.com/medline/citation/32511417/Single_dose_replicating_RNA_vaccine_induces_neutralizing_antibodies_against_SARS_CoV_2_in_nonhuman_primates_ L2 - https://doi.org/10.1101/2020.05.28.121640 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.